Senores Pharmaceuticals Limited submitted a disclosure to BSE Limited and National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was in response to a letter from the exchanges dated September 21, 2026, seeking clarification regarding movement in trading volume of the company's securities.
The company confirmed that it is in full compliance with SEBI LODR Regulations and has been promptly informing the stock exchanges about all events and information that have a bearing on the company's operation or performance.
The company specifically stated that there is no undisclosed price-sensitive information or any impending announcement/corporate action that needs to be disclosed to the exchanges at this time.
Senores Pharmaceuticals assured that it will continue to promptly inform the exchanges of all material events/information/actions as required under SEBI (LODR) Regulations 2015.
Financial Impact
No financial impact disclosed. The company confirmed no material undisclosed information affecting operations or performance.